Eplerenone

證據等級: L5

預測適應症: 5 個

Eplerenone: From Heart Failure / Hypertension to Pulmonary Hypertension Owing to Lung Disease and/or Hypoxia

One-Sentence Summary

Eplerenone is a selective mineralocorticoid receptor (MR) antagonist, with established use internationally for heart failure post-myocardial infarction and hypertension, though it is not currently marketed in Canada. The TxGNN model predicts it may be effective for Pulmonary Hypertension Owing to Lung Disease and/or Hypoxia (WHO Group 3 PH), based on the known role of aldosterone/MR signalling in pulmonary vascular remodelling. Supporting evidence is limited to mechanistic rationale and 20 retrieved publications — none of which directly study eplerenone in this indication — and no registered clinical trials were identified.

Quick Overview

Item	Content
Original Indication	Heart failure post-MI; hypertension (internationally established; not approved in Canada)
Predicted New Indication	Pulmonary hypertension owing to lung disease and/or hypoxia (WHO Group 3 PH)
TxGNN Prediction Score	99.50%
Evidence Level	L4
Canada Market Status	✗ Not marketed
Number of DINs	0
Recommended Decision	Hold (Research Question)

Why Is This Prediction Reasonable?

Eplerenone is a highly selective mineralocorticoid receptor (MR) antagonist. Unlike spironolactone, it has minimal affinity for androgen or progesterone receptors, which reduces off-target side effects. Internationally, it is approved for reducing cardiovascular mortality in stable patients with left ventricular dysfunction and clinical heart failure following acute myocardial infarction, and for essential hypertension. Detailed mechanism of action data was not available in this Evidence Pack; however, its pharmacological class is well established in the literature.

The mechanistic rationale for this prediction centres on the aldosterone/MR axis in pulmonary hypertension (PH). Aldosterone levels are elevated in patients with pulmonary arterial hypertension (PAH), and MR activation is believed to drive pulmonary vascular fibrosis, smooth muscle remodelling, and right ventricular (RV) hypertrophy. Animal model studies have demonstrated that MR antagonism can attenuate RV pressure overload — providing a plausible biological basis for this prediction.

However, the predicted indication is WHO Group 3 PH (PH secondary to lung disease or hypoxia), which differs pathophysiologically from Group 1 PAH. In Group 3 PH, hypoxic pulmonary vasoconstriction and the underlying lung disease are the primary drivers, and the degree to which aldosterone-mediated pathways contribute is not well characterised. No direct human clinical trial data exists for eplerenone in this setting, and in patients with concomitant chronic lung disease and renal impairment, the risk of hyperkalaemia — eplerenone’s principal safety concern — would require careful evaluation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Important caveat: The 20 publications retrieved via the automated PubMed search query for eplerenone + pulmonary hypertension/hypoxia are general hypoxia biology reviews and do not directly study eplerenone in pulmonary hypertension. They are listed below for completeness but provide only indirect contextual support.

PMID	Year	Type	Journal	Key Findings
11172576	2000	Review	Respiratory Care Clinics of North America	Describes the four core mechanisms of hypoxaemia (hypoventilation, V/Q mismatch, shunt, diffusion), foundational to understanding Group 3 PH pathophysiology
21328446	2011	Review	Journal of Cellular Biochemistry	Broad review of cellular hypoxia responses including angiogenesis and pH homeostasis; relevant background on HIF-driven vascular adaptation
27423661	2016	Review	Cell and Tissue Research	Hypoxia and HIF-1 signalling in tissue fibrosis; contextually relevant to pulmonary vascular remodelling
31961750	2020	Review	Annual Review of Immunology	Hypoxia in innate immunity and inflammation — highlights physiologic vs. inflammatory hypoxia as distinct compartments
33862277	2021	Review	Ageing Research Reviews	Hypoxia and neurodegeneration; limited relevance to PH but contextualises systemic hypoxia consequences
34535359	2021	Review	Clinical Oncology (RCR)	Therapeutic strategies targeting tumour hypoxia; limited relevance to PH but discusses HIF pathway intervention
33278780	2021	Basic Science	Redox Biology	Metabolic reprogramming of keloid fibroblasts under hypoxia via HIF-1α/PI3K/AKT; indirect mechanistic context
34618295	2022	Review	Metabolic Brain Disease	Acute and chronic hypoxia causing cognitive impairment; not relevant to PH indication
37328448	2023	Basic Science	Advanced Science	NAT10/HIF-1α glycolysis loop in gastric cancer; not relevant to eplerenone or PH
40347693	2025	Review	Redox Biology	Hypoxia in multiple sclerosis pathology and vascular dysfunction; not directly relevant to PH

Canada Market Information

Eplerenone is not currently marketed in Canada. No Drug Identification Numbers (DINs) are on file.

For reference: eplerenone is approved in the United States (Inspra®, Pfizer) and the European Union for post-MI heart failure and hypertension. A Health Canada new drug submission would be required before any Canadian use.

Safety Considerations

Please refer to the package insert for safety information.

Note: Although formal package insert data was not available for this Evidence Pack, eplerenone’s well-known class safety profile includes risk of hyperkalaemia (particularly with eGFR < 30 mL/min, use of ACE inhibitors/ARBs, or diabetes), which is especially relevant in the Group 3 PH patient population who commonly have concurrent CKD or advanced lung disease.

Conclusion and Next Steps

Decision: Hold (Research Question)

Rationale: The TxGNN prediction score is high (99.50%), and there is a plausible mechanistic rationale linking aldosterone/MR pathways to pulmonary vascular remodelling in PH. However, the 20 retrieved publications do not directly address eplerenone in pulmonary hypertension — they are general hypoxia biology reviews with no clinical or preclinical data on the drug-disease pair. With zero registered clinical trials and no direct human evidence, this candidate remains at hypothesis stage only (Evidence Level L4). Additionally, the WHO Group 3 PH population carries elevated hyperkalaemia risk that would need independent safety characterisation.

To proceed, the following is needed:

Targeted literature search: Conduct a dedicated search for eplerenone (or class: MR antagonists / spironolactone) specifically in pulmonary hypertension models or patients — the current 20 papers are non-specific
Preclinical evidence review: Identify animal model studies (monocrotaline or hypoxia-induced PH models) that tested MR antagonists to establish whether L4 evidence truly exists
MOA documentation: Obtain formal DrugBank/TFDA mechanism of action data to enable mechanistic-link scoring
Safety assessment for Group 3 PH population: Model hyperkalaemia risk given typical comorbidity profile (CKD, diuretics, ACEi co-use) in this patient population
Health Canada regulatory pathway: eGFR thresholds and contraindications would need alignment with Canadian labelling standards before any clinical investigation
Expert consultation: Pulmonology/respirology opinion on whether MR antagonism has a biologically distinct role in Group 3 vs. Group 1 PH to determine if a research protocol is warranted
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.